Outcomes of 23 patients diagnosed with New Delhi metallo-beta-lactamase (NDM)-producing Klebsiella pneumoniae infection treated with ceftazidime/avibactam and aztreonam at a single center in Poland
European Journal of Clinical Microbiology & Infectious Diseases · 2024-08 · 43 (8) · 1579-1587
DOI: 10.1007/s10096-024-04859-y ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Clinical Microbiology & Infectious Diseases, online erschienen am 29.05.2024. Verfasst von Aneta Guzek und 5 weiteren Autor:innen. Beteiligte Einrichtung: Section of Microbiology, Department of Laboratory Diagnostics, Military Institute of Medicine-National Research Institute, Warsaw, Poland. Hauptthemen laut MEDLINE: Klebsiella pneumoniae, Aztreonam, beta-Lactamases, Azabicyclo Compounds. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
Amongst all etiologic hospital-acquired infection factors, K. pneumoniae strains producing New Delhi metallo-β-lactamase (KP-NDM) belong to pathogens with the most effective antibiotic resistance mechanisms. Clinical guidelines recommend using ceftazidime/avibactam with aztreonam (CZA + AT) as the preferred option for NDM-producing Enterobacterales. However, the number of observations on such treatment regimen is limited. This retrospective study reports the clinical and microbiological outcomes of 23 patients with KP-NDM hospital-acquired infection treated with CZA + AT at a single center in Poland.
Methods
The isolates were derived from the urine, lungs, blood, peritoneal cavity, wounds, and peritonsillar abscess. In microbiological analysis, mass spectrometry for pathogen identification, polymerase chain reaction, or an immunochromatographic assay for detection of carbapenemase, as well as VITEK-2 system, broth microdilution, and microdilution in agar method for antimicrobial susceptibility tests were used, depending of the pathogens’ nature. CZA was administered intravenously (IV) at 2.5 g every eight hours in patients with normal kidney function, and aztreonam was administered at 2 g every eight hours IV. Such dosage was modified when renal function was reduced.
Results
KP-NDM was eradicated in all cases. Four patients (17.4%) died: three of them had a neoplastic disease, and one - a COVID-19 infection.
Conclusion
The combination of CZA + AT is a safe and effective therapy for infections caused by KP-NDM, both at the clinical and microbiological levels. The synergistic action of all compounds resulted in a good agreement between the clinical efficacy of CZA + AT and the results of in vitro susceptibility testing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Section of Microbiology, Department of Laboratory Diagnostics, Military Institute of Medicine-National Research Institute, Warsaw, Poland.
- Department of Anesthesiology and Intensive Therapy, Military Institute of Medicine-National Research Institute, Warsaw, Poland.
- Department of Anesthesiology and Intensive Therapy, Military Institute of Aviation Medicine, Warsaw, Poland. dtomaszewski@wiml.waw.pl.
- Department of Laboratory Diagnostics, Military Institute of Medicine-National Research Institute, Warsaw, Poland.
- Department of Infectious Diseases and Allergology, Military Institute of Medicine-National Research Institute, Warsaw, Poland.
Zitieren
APA
Guzek, A., Rybicki, Z., Tomaszewski, D., Mackiewicz, K., Piechota, W., & Chciałowski, A. (2024). Outcomes of 23 patients diagnosed with New Delhi metallo-beta-lactamase (NDM)-producing Klebsiella pneumoniae infection treated with ceftazidime/avibactam and aztreonam at a single center in Poland. European Journal of Clinical Microbiology & Infectious Diseases, 43(8), 1579-1587. https://doi.org/10.1007/s10096-024-04859-y
Vancouver
Guzek A, Rybicki Z, Tomaszewski D, Mackiewicz K, Piechota W, Chciałowski A. Outcomes of 23 patients diagnosed with New Delhi metallo-beta-lactamase (NDM)-producing Klebsiella pneumoniae infection treated with ceftazidime/avibactam and aztreonam at a single center in Poland. European Journal of Clinical Microbiology & Infectious Diseases. 2024;43(8):1579-1587. doi:10.1007/s10096-024-04859-y
BibTeX
@article{Guzek2024,
author = {Guzek, Aneta and Rybicki, Zbigniew and Tomaszewski, Dariusz and Mackiewicz, Katarzyna and Piechota, Wiesław and Chciałowski, Andrzej},
title = {Outcomes of 23 patients diagnosed with New Delhi metallo-beta-lactamase (NDM)-producing Klebsiella pneumoniae infection treated with ceftazidime/avibactam and aztreonam at a single center in Poland},
journal = {European Journal of Clinical Microbiology & Infectious Diseases},
year = {2024},
volume = {43},
number = {8},
pages = {1579--1587},
doi = {10.1007/s10096-024-04859-y}
}
EUVIMED